Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $45.67 billion. The enterprise value is $58.91 billion.
| Market Cap | 45.67B |
| Enterprise Value | 58.91B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.17 billion shares outstanding. The number of shares has increased by 2.24% in one year.
| Current Share Class | 1.17B |
| Shares Outstanding | 1.17B |
| Shares Change (YoY) | +2.24% |
| Shares Change (QoQ) | -1.19% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 71.51% |
| Float | 1.09B |
Valuation Ratios
The trailing PE ratio is 66.85 and the forward PE ratio is 14.56. Teva Pharmaceutical's PEG ratio is 1.82.
| PE Ratio | 66.85 |
| Forward PE | 14.56 |
| PS Ratio | 2.63 |
| Forward PS | 2.71 |
| PB Ratio | 6.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 33.85 |
| P/OCF Ratio | 24.02 |
| PEG Ratio | 1.82 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.79, with an EV/FCF ratio of 43.68.
| EV / Earnings | 83.34 |
| EV / Sales | 3.40 |
| EV / EBITDA | 13.79 |
| EV / EBIT | 17.94 |
| EV / FCF | 43.68 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 2.18.
| Current Ratio | 0.88 |
| Quick Ratio | 0.46 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | 12.54 |
| Interest Coverage | 3.81 |
Financial Efficiency
Return on equity (ROE) is 9.69% and return on invested capital (ROIC) is 15.21%.
| Return on Equity (ROE) | 9.69% |
| Return on Assets (ROA) | 5.13% |
| Return on Invested Capital (ROIC) | 15.21% |
| Return on Capital Employed (ROCE) | 13.55% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | $510,015 |
| Profits Per Employee | $20,795 |
| Employee Count | 33,950 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.45 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $12.00 million in taxes.
| Income Tax | 12.00M |
| Effective Tax Rate | 1.67% |
Stock Price Statistics
The stock price has increased by +103.37% in the last 52 weeks. The beta is 0.80, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +103.37% |
| 50-Day Moving Average | 36.10 |
| 200-Day Moving Average | 33.44 |
| Relative Strength Index (RSI) | 57.46 |
| Average Volume (20 Days) | 5,069,254 |
Short Selling Information
The latest short interest is 31.48 million, so 2.71% of the outstanding shares have been sold short.
| Short Interest | 31.48M |
| Short Previous Month | 34.32M |
| Short % of Shares Out | 2.71% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 57.43 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $17.32 billion and earned $706.00 million in profits. Earnings per share was $0.60.
| Revenue | 17.32B |
| Gross Profit | 9.08B |
| Operating Income | 3.28B |
| Pretax Income | 719.00M |
| Net Income | 706.00M |
| EBITDA | 4.27B |
| EBIT | 3.28B |
| Earnings Per Share (EPS) | $0.60 |
Balance Sheet
The company has $3.66 billion in cash and $16.89 billion in debt, with a net cash position of -$13.24 billion or -$11.36 per share.
| Cash & Cash Equivalents | 3.66B |
| Total Debt | 16.89B |
| Net Cash | -13.24B |
| Net Cash Per Share | -$11.36 |
| Equity (Book Value) | 7.76B |
| Book Value Per Share | 6.65 |
| Working Capital | -1.89B |
Cash Flow
In the last 12 months, operating cash flow was $1.90 billion and capital expenditures -$551.00 million, giving a free cash flow of $1.35 billion.
| Operating Cash Flow | 1.90B |
| Capital Expenditures | -551.00M |
| Depreciation & Amortization | 988.00M |
| Net Borrowing | -474.00M |
| Free Cash Flow | 1.35B |
| FCF Per Share | $1.16 |
Margins
Gross margin is 52.46%, with operating and profit margins of 18.94% and 4.08%.
| Gross Margin | 52.46% |
| Operating Margin | 18.94% |
| Pretax Margin | 4.15% |
| Profit Margin | 4.08% |
| EBITDA Margin | 24.65% |
| EBIT Margin | 18.94% |
| FCF Margin | 7.78% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.24% |
| Shareholder Yield | -2.24% |
| Earnings Yield | 1.55% |
| FCF Yield | 2.95% |
Analyst Forecast
The average price target for Teva Pharmaceutical is $44.00, which is 12.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.00 |
| Price Target Difference | 12.27% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 1.61% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.68 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.68 |
| Piotroski F-Score | 7 |